title: [Changes of proteomics in the lung of rats subjected to acrolein inhalation after enalapril administration].
abstract: OBJECTIVE
  To study the molecular mechanism of enalapril on rat chronic bronchopneumonia model with proteomics method.
  
  
  METHODS
  Enalapril treatment applied to the recovery of chronic bronchopneumonia in rats, after enalapril administration, two-dimensional electrophoresis and mass spectrometry were performed to analyze the difference of the peptide finger print map and amino acid sequence of rat lung tissues in acrolein inhalation group and enalapril treatment group.
  
  
  RESULTS
  Three differential protein spots from average 545 protein spots were found in lung tissues of two groups. These protein spots were identified as glyceraldehyde-3-phosphate dehydrogenase, T-kininogen 1 precursor and dihydropyrimidinase-like 2 with mass spectrometry. The significant upregulation in the level of dihydropyrimidinase-like 2, downregulation of glyceraldehyde-3-phosphate dehydrogenase, and the lose of T-kininogen 1 precursor in enalapril treatment group were observed.
  
  
  CONCLUSIONS
  The expression difference in three proteins might contribute to the preventive role of enalapril on acrolein inhalation induced rat chronic bronchopneumonia.
authors.affiliation: People's Hospital of Yunnan Province, Kunming 65000, China.
authors.forename: Yun-hui
authors.initials: YH
authors.lastname: Zhang
authors.forename: Shan
authors.initials: S
authors.lastname: Zhao
authors.forename: Sheng-lan
authors.initials: SL
authors.lastname: Wang
authors.forename: Bin
authors.initials: B
authors.lastname: Yuan
authors.forename: Zhao-jun
authors.initials: ZJ
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Yun-chao
authors.initials: YC
authors.lastname: Huang
mesh_terms: D000171:Acrolein / Q000008:administration & dosage / Q000633:toxicity*; D000280:Administration, Inhalation; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001996:Bronchopneumonia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D008168:Lung / Q000378:metabolism / Q000473:pathology; D055370:Lung Injury / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D008297:Male; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics / Q000379:methods; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020543:Proteome; D004656:Enalapril; D000171:Acrolein